

The Toxicologic Pathologist and the Regulatory Community

Sponsored by the Society of Toxicologic Pathology and the CL Davis, DVM Foundation and kindly hosted by the Uniformed Services University of the Health Sciences, Bethesda, Maryland

Friday, 14 October 2011

Agenda

8:00 to 8:15: Welcome and introductory remarks

Dr. Kevin Keane, Huntingdon Life Sciences, East Millstone, NJ

8:15 to 8:50: *"The Toxicologist and the Pathologist—Working Together in Drug Development"*

Carol S. Auletta, MBA, DABT, CertRAC; Director, Huntingdon Life Sciences, East Millstone, NJ

8:50 to 9:40: *"Histopathology Assessment of Preclinical Safety Studies: Current Practices and Challenges"*

Marlon C. Rebelatto, DVM, Ph.D., DACVP; Senior Pathologist, Experimental Pathology, Translational Sciences –Research, MedImmune, LLC, Gaithersburg, MD

9:40 to 10:00: Morning break

10:00 to 10:50: *"Identifying and Justifying Changes Associated with Stress in Preclinical Toxicity Testing"*

Dianne M. Creasy, PhD, Dip RCPATH(tox), FRCPath, Senior Scientific Advisor and Consultant Pathologist, Huntingdon Life Sciences, East Millstone, NJ

10:50 to 11:40: *"Integration of Clinical and Anatomic Pathology Data Sets in Toxicology Studies"*

Vincent P. Meador, DVM, PhD, DACVP, Global Scientific Leader, General Toxicology and Pathology, Nonclinical Safety Assessment, Covance, Inc., Seattle, WA

11:40 to 1:05: Lunch

1:05 to 1:50: *"Carcinogenicity Testing of Pharmaceuticals: Past, Present and Future"*

David Jacobson-Kram, Ph.D., DABT, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD

1:50 to 2:10: Afternoon break

2:10 to 2:55: Panel Discussion with all speakers

Moderator: Dr. Sarah Hale, Joint Pathology Center, Silver Spring, MD



**Society of
Toxicologic
Pathology**

